I am an Associate Professor in the Department of Neurology and the Head of the Laboratory for Genomics, Pharmacogenomics and Precision Health (PRECISE) at the Linda T. and John A Mellowes Center for Genomic Sciences and Precision Medicine at the Medical College of Wisconsin. Prior to that, I served as the Head of the Pharmacogenomics and Personalized Medicine Program at the Agency for Science Technology and Research (A\*STAR) Singapore, as Assistant Professor (joint appointment) in the Department of Medicine and the Department of Biomedical Informatics at the Yong Loo Lin School of Medicine at the National University of Singapore. I also served as a Faculty at the Centre for Precision Health (CPH) at the National University Health System (NUHS) in Singapore, the Pharmacogenomics Domain Expert for the Precision Medicine Coordination Office (PMCO) of the Ministry of Health, Singapore and on the NIH ClinGen, Pharmacogenomics Working Group (CLINGEN\_PGXWG) and the Executive board of the Pharmacogenomics Global Research Network (PGRN). I bring a wealth of experience, leadership, and scientific expertise in cutting- edge "Genomics, Pharmacogenomics and Precision Health Research and Innovations". My recent work focuses on Genomics, Pharmacogenomics and Precision Health research in Oncology and Neuroscience. As a Principal Investigator or Co-Investigator on several University, NIH, CHIR, and NMRC funded grants, I have successfully developed and implemented multiple projects focused on genomics, pharmacogenomics and precision health; collaborated with many global researchers; and have produced several high impact peer-reviewed publications in top scientific journals including Nature Genetics and JAMA ONCOLOGY. I have received several awards and recognition for my academic and scientific contributions, including the British Columbia Children’s Hospital Research Institute Outstanding Achievement award, Boehringer Ingelheim Award, Canadian Society of Pharmacology and Therapeutics Publication Award and the American Society of Human Genetics outstanding papers award. I am currently a member of several scientific consortia and working groups including the PGRN Psychiatry Special Interest Group, NIH CLINGEN\_PGXWG Nomenclature Survey Subgroup, NIH CLINGEN\_PGXWG Gene-Drug Validity Subgroup, Pharmacogene Variation Consortium and CPNDS Pharmacogenomics Clinical Practice Recommendations Group. I am also a member of several academic and professional organizations including the Pharmacogenomics Global Research Network, American Association of Pharmaceutical Scientists, British Pharmacological Society, European Society of Pharmacogenomics and Personalized Therapy, American Society of Human Genetics, Canadian Society for Pharmaceutical Sciences, Canadian Society of Pharmacology and Therapeutics, International Genetic Epidemiology Society, European Society of Human Genetics and African Society of Human Genetics. I have served on the Editorial Board of several journals including the Journal of Population Therapeutics and Clinical Pharmacology and as an editorial reviewer and ad hoc reviewer for several journals including Nature Genetics, Circulation – Journal of the American Heart Association, Mayo Clinic Proceedings, MDPI Pharmaceutic, Pharmacogenetics and Genomics, Canadian Journal of Cardiology, Clinical Genetics and Pharmacogenomics – Future Medicine.

A/Prof FOLEFAC AMINKENG

Associate Professor (Genomics, Pharmacogenomics, Precision Health and Health Disparities), Medical College of Wisconsin

Research Expertise

Genomics

Pharmacogenomics and Precision Health

About

Publications

Pharmacogenomic strategies for the prevention of anthracycline-induced heart failure: A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

Drug Metabolism and Pharmacokinetics / Jan 01, 2017

Ross, C. (2017). Pharmacogenomic strategies for the prevention of anthracycline-induced heart failure: A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Drug Metabolism and Pharmacokinetics, 32(1), S73–S74. https://doi.org/10.1016/j.dmpk.2016.10.292

Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

British Journal of Clinical Pharmacology / Jun 30, 2016

Aminkeng, F., Ross, C. J. D., Rassekh, S. R., Hwang, S., Rieder, M. J., Bhavsar, A. P., Smith, A., Sanatani, S., Gelmon, K. A., Bernstein, D., Hayden, M. R., Amstutz, U., & Carleton, B. C. (2016). Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity. British Journal of Clinical Pharmacology, 82(3), 683–695. Portico. https://doi.org/10.1111/bcp.13008

The emerging era of pharmacogenomics: current successes, future potential, and challenges

Clinical Genetics / May 09, 2014

Lee, J. W., Aminkeng, F., Bhavsar, A. P., Shaw, K., Carleton, B. C., Hayden, M. R., & Ross, C. J. D. (2014). The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clinical Genetics, 86(1), 21–28. Portico. https://doi.org/10.1111/cge.12392

Unbiased Profiling of Isogenic Huntington Disease hPSC-Derived CNS and Peripheral Cells Reveals Strong Cell-Type Specificity of CAG Length Effects

Cell Reports / Feb 01, 2019

Ooi, J., Langley, S. R., Xu, X., Utami, K. H., Sim, B., Huang, Y., Harmston, N. P., Tay, Y. L., Ziaei, A., Zeng, R., Low, D., Aminkeng, F., Sobota, R. M., Ginhoux, F., Petretto, E., & Pouladi, M. A. (2019). Unbiased Profiling of Isogenic Huntington Disease hPSC-Derived CNS and Peripheral Cells Reveals Strong Cell-Type Specificity of CAG Length Effects. Cell Reports, 26(9), 2494-2508.e7. https://doi.org/10.1016/j.celrep.2019.02.008

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics / Feb 20, 2018

Kay, C., Collins, J. A., Wright, G. E. B., Baine, F., Miedzybrodzka, Z., Aminkeng, F., Semaka, A. J., McDonald, C., Davidson, M., Madore, S. J., Gordon, E. S., Gerry, N. P., Cornejo‐Olivas, M., Squitieri, F., Tishkoff, S., Greenberg, J. L., Krause, A., & Hayden, M. R. (2018). The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 177(3), 346–357. Portico. https://doi.org/10.1002/ajmg.b.32618

Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes

Clinical Pharmacology & Therapeutics / Aug 17, 2018

Wright, G. E. B., Amstutz, U., Drögemöller, B. I., Shih, J., Rassekh, S. R., Hayden, M. R., Carleton, B. C., & Ross, C. J. D. (2018). Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clinical Pharmacology & Therapeutics, 105(2), 402–410. Portico. https://doi.org/10.1002/cpt.1179

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer

JAMA Oncology / Nov 01, 2017

Drögemöller, B. I., Monzon, J. G., Bhavsar, A. P., Borrie, A. E., Brooks, B., Wright, G. E. B., Liu, G., Renouf, D. J., Kollmannsberger, C. K., Bedard, P. L., Aminkeng, F., Amstutz, U., Hildebrand, C. A., Gunaretnam, E. P., Critchley, C., Chen, Z., Brunham, L. R., Hayden, M. R., Ross, C. J. D., … Carleton, B. C. (2017). Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncology, 3(11), 1558. https://doi.org/10.1001/jamaoncol.2017.0502

Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients

PLOS ONE / Oct 16, 2017

Chan, S. L., Chua, A. P. G., Aminkeng, F., Chee, C. B. E., Jin, S., Loh, M., Gan, S. H., Wang, Y. T., & Brunham, L. R. (2017). Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLOS ONE, 12(10), e0186200. https://doi.org/10.1371/journal.pone.0186200

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent

The Pharmacogenomics Journal / Apr 16, 2013

Aminkeng, F., Ross, C. J. D., Rassekh, S. R., Brunham, L. R., Sistonen, J., Dube, M.-P., Ibrahim, M., Nyambo, T. B., Omar, S. A., Froment, A., Bodo, J.-M., Tishkoff, S., Carleton, B. C., & Hayden, M. R. (2013). Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. The Pharmacogenomics Journal, 14(2), 160–170. https://doi.org/10.1038/tpj.2013.13

Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study

Cancers / Mar 15, 2021

Lee, P. Y., Oen, K. Q. X., Lim, G. R. S., Hartono, J. L., Muthiah, M., Huang, D. Q., Teo, F. S. W., Li, A. Y., Mak, A., Chandran, N. S., Tan, C. L., Yang, P., Tai, E. S., Ng, K. W. P., Vijayan, J., Chan, Y. C., Tan, L. L., Lee, M. B.-H., Chua, H. R., … Tay, S. H. (2021). Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. Cancers, 13(6), 1308. https://doi.org/10.3390/cancers13061308

Association between the TCF7L2 rs12255372 (G/T) gene polymorphism and type 2 diabetes mellitus in a Cameroonian population: a pilot study

Clinical and Translational Medicine / Apr 23, 2015

Nanfa, D., Sobngwi, E., Atogho‐Tiedeu, B., Noubiap, J. J. N., Donfack, O. S., Mofo, E. P. M., Guewo‐Fokeng, M., Nguimmo Metsadjio, A., Ndonwi Ngwa, E., Pokam Fosso, P., Djahmeni, E., Djokam‐Dadjeu, R., Evehe, M., Aminkeng, F., Mbacham, W. F., & Mbanya, J. C. (2015). Association between the TCF7L2 rs12255372 (G/T) gene polymorphism and type 2 diabetes mellitus in a Cameroonian population: a pilot study. Clinical and Translational Medicine, 4(1). Portico. https://doi.org/10.1186/s40169-015-0058-1

Contribution of the TCF7L2 rs7903146 (C/T) gene polymorphism to the susceptibility to type 2 diabetes mellitus in Cameroon

Journal of Diabetes & Metabolic Disorders / Apr 14, 2015

Guewo-Fokeng, M., Sobngwi, E., Atogho-Tiedeu, B., Donfack, O. S., Noubiap, J. J. N., Ngwa, E. N., Mato-Mofo, E. P., Fosso, P. P., Djahmeni, E., Djokam-Dadjeu, R., Evehe, M.-S., Aminkeng, F., Mbacham, W. F., & Mbanya, J. C. (2015). Contribution of the TCF7L2 rs7903146 (C/T) gene polymorphism to the susceptibility to type 2 diabetes mellitus in Cameroon. Journal of Diabetes & Metabolic Disorders, 14(1). https://doi.org/10.1186/s40200-015-0148-z

Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature

Frontiers in Immunology / Jan 28, 2022

Tay, S. H., Toh, M. M. X., Thian, Y. L., Vellayappan, B. A., Fairhurst, A.-M., Chan, Y. H., Aminkeng, F., Bharwani, L. D., Huang, Y., Mak, A., & Wong, A. S. C. (2022). Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.807050

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

Nature Genetics / Jul 16, 2018

Kowalec, K., Wright, G. E. B., Drögemöller, B. I., Aminkeng, F., Bhavsar, A. P., Kingwell, E., Yoshida, E. M., Traboulsee, A., Marrie, R. A., Kremenchutzky, M., Campbell, T. L., Duquette, P., Chalasani, N., Wadelius, M., Hallberg, P., Xia, Z., De Jager, P. L., Denny, J. C., Davis, M. F., … Carleton, B. C. (2018). Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nature Genetics, 50(8), 1081–1085. https://doi.org/10.1038/s41588-018-0168-y

IFIH1 gene polymorphisms in type 1 diabetes: Genetic association analysis and genotype–phenotype correlation in the Belgian population

Human Immunology / Sep 01, 2009

Aminkeng, F., Van Autreve, J. E., Weets, I., Quartier, E., Van Schravendijk, C., Gorus, F. K., & Van der Auwera, B. J. (2009). IFIH1 gene polymorphisms in type 1 diabetes: Genetic association analysis and genotype–phenotype correlation in the Belgian population. Human Immunology, 70(9), 706–710. https://doi.org/10.1016/j.humimm.2009.06.013

Risk factors for immune‐related adverse events from anti‐PD‐1 or anti‐PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

International Journal of Cancer / Oct 13, 2021

Huang, Y., Soon, Y. Y., Aminkeng, F., Tay, S. H., Ang, Y., Kee, A. C. L., Goh, B. C., Wong, A. S. C., & Soo, R. A. (2021). Risk factors for immune‐related adverse events from <scp>anti‐PD</scp>‐1 or anti‐<scp>PD‐L1</scp> treatment in an Asian cohort of nonsmall cell lung cancer patients. International Journal of Cancer, 150(4), 636–644. Portico. https://doi.org/10.1002/ijc.33822

Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA‐C1 ligand binding

Tissue Antigens / May 15, 2009

Ramos‐Lopez, E., Scholten, F., Aminkeng, F., Wild, C., Kalhes, H., Seidl, C., Tonn, T., Van der Auwera, B., & Badenhoop, K. (2009). Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA‐C1 ligand binding. Tissue Antigens, 73(6), 599–603. Portico. https://doi.org/10.1111/j.1399-0039.2009.01252.x

MICA is Associated with Type 1 Diabetes in the Belgian Population, Independent of HLA-DQ

Human Immunology / Jan 01, 2006

Van Autreve, J. E., Koeleman, B. P. C., Quartier, E., Aminkeng, F., Weets, I., Gorus, F. K., & Van der Auwera, B. J. R. (2006). MICA is Associated with Type 1 Diabetes in the Belgian Population, Independent of HLA-DQ. Human Immunology, 67(1–2), 94–101. https://doi.org/10.1016/j.humimm.2006.02.032

Pharmacogenomic screening for anthracycline‐induced cardiotoxicity in childhood cancer

British Journal of Clinical Pharmacology / Mar 19, 2017

Aminkeng, F., Ross, C. J. D., Rassekh, S. R., Rieder, M. J., Bhavsar, A. P., Sanatani, S., Bernstein, D., Hayden, M. R., Amstutz, U., & Carleton, B. C. (2017). Pharmacogenomic screening for anthracycline‐induced cardiotoxicity in childhood cancer. British Journal of Clinical Pharmacology, 83(5), 1143–1145. Portico. https://doi.org/10.1111/bcp.13218

Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: Relation to autoantibody status and comparison with Belgian patients

Diabetes Research and Clinical Practice / Jan 01, 2014

Asanghanwa, M., Gorus, F. K., Weets, I., der Auwera, B. V., Aminkeng, F., Mbunwe, E., Goubert, P., Verhaeghen, K., Sobngwi, E., Wenzlau, J. M., Hutton, J. C., Pipeleers, D. G., Keymeulen, B., Mbanya, J.-C. N., & van Schravendijk, C. (2014). Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: Relation to autoantibody status and comparison with Belgian patients. Diabetes Research and Clinical Practice, 103(1), 97–105. https://doi.org/10.1016/j.diabres.2013.11.013

Neither an intronic CA repeat within the CD48 gene nor the HERV‐K18 polymorphisms are associated with type 1 diabetes

Tissue Antigens / Jul 06, 2006

Ramos‐Lopez, E., Ghebru, S., Van Autreve, J., Aminkeng, F., Herwig, J., Seifried, E., Seidl, C., Van der Auwera, B., & Badenhoop, K. (2006). Neither an intronic CA repeat within the CD48 gene nor the HERV‐K18 polymorphisms are associated with type 1 diabetes. Tissue Antigens, 68(2), 147–152. Portico. https://doi.org/10.1111/j.1399-0039.2006.00637.x

Pharmacogenomic diversity in Singaporean populations and Europeans

The Pharmacogenomics Journal / May 27, 2014

Brunham, L. R., Chan, S. L., Li, R., Aminkeng, F., Liu, X., Saw, W. Y., Ong, R. T. H., Pillai, E. N., Carleton, B. C., Toh, D., Tan, S. H., Koo, S. H., Lee, E. J. D., Chia, K. S., Ross, C. J. D., Hayden, M. R., Sung, C., & Teo, Y. Y. (2014). Pharmacogenomic diversity in Singaporean populations and Europeans. The Pharmacogenomics Journal, 14(6), 555–563. https://doi.org/10.1038/tpj.2014.22

HINT1 mutations define a novel disease entity – autosomal recessive axonal neuropathy with neuromyotonia

Clinical Genetics / Jan 01, 2013

Aminkeng, F. (2013). <scp>HINT1</scp> mutations define a novel disease entity – autosomal recessive axonal neuropathy with neuromyotonia. Clinical Genetics, 83(1), 31–32. Portico. https://doi.org/10.1111/cge.12030

Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population

Human Immunology / Dec 01, 2010

Aminkeng, F., Weets, I., Van Autreve, J. E., Koeleman, B. P. C., Quartier, E., Van Schravendijk, C., Gorus, F. K., & Van der Auwera, B. J. R. (2010). Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population. Human Immunology, 71(12), 1233–1237. https://doi.org/10.1016/j.humimm.2010.09.006

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Thoracic Cancer / Sep 30, 2022

Huang, Y., Zhao, J. J., Soon, Y. Y., Wong, A., Aminkeng, F., Ang, Y., Asokumaran, Y., Low, J. L., Lee, M., Choo, J. R. E., Chan, G., Kee, A., Tay, S. H., Goh, B. C., & Soo, R. A. (2022). Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage <scp>III</scp> non‐small cell lung cancer. Thoracic Cancer, 13(22), 3152–3161. Portico. https://doi.org/10.1111/1759-7714.14667

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers

Clinical Pharmacology & Therapeutics / Jun 12, 2023

Oni‐Orisan, A., Tuteja, S., Hoffecker, G., Smith, D. M., Castrichini, M., Crews, K. R., Murphy, W. A., Nguyen, N. H. K., Huang, Y., Lteif, C., Friede, K. A., Tantisira, K., Aminkeng, F., Voora, D., Cavallari, L. H., Whirl‐Carrillo, M., Duarte, J. D., & Luzum, J. A. (2023). An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. Clinical Pharmacology & Therapeutics, 114(2), 275–287. Portico. https://doi.org/10.1002/cpt.2957

Genome-wide Scan Identifies Association Between an Interferon Regulatory Factor Variant and Interferon-beta Induced Liver Injury in Multiple Sclerosis Patients

Journal of Pharmacological and Toxicological Methods / Nov 01, 2017

Kowalec, K., Wright, G. E. B., Drögemöller, B. I., Aminkeng, F., Bhavsar, A. P., Kingwell, E., Yoshida, E. M., Traboulsee, A., Marrie, R. A., Kremenchutzky, M., Campbell, T. L., Duquette, P., Chalasani, N., Wadelius, M., Hallberg, P., Xia, Z., De Jager, P., Ross, C., Tremlett, H., & Carleton, B. (2017). Genome-wide Scan Identifies Association Between an Interferon Regulatory Factor Variant and Interferon-beta Induced Liver Injury in Multiple Sclerosis Patients. Journal of Pharmacological and Toxicological Methods, 88, 173. https://doi.org/10.1016/j.vascn.2017.09.019

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

Journal of Thoracic Oncology / Nov 01, 2023

Huang, Y., Aminkeng, F., Zhao, J. J., Soon, Y. Y., Kee, A., Ang, Y., Low, J. L., Tay, S. H., Wong, A., Bharwani, L. D., Goh, B. C., & Soo, R. A. (2023). P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC. Journal of Thoracic Oncology, 18(11), S309–S310. https://doi.org/10.1016/j.jtho.2023.09.532

A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Blood / Nov 15, 2022

Lee, J., Tabatabaeian, H., Poon, M. L., Somasundaram, N., Xin, L., Yuen, Y. C., Teoh, C. M., Yan, B., Chan, E. H. L., Chee, Y. L., De Mel, S., Zhang, B., Chew, X. H., Tang, T., Khor, C. C., Ngeow, J. Y. Y., Ong, C. K., Lim, S. T., Chng, W. J., … Aminkeng, F. (2022). A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury. Blood, 140(Supplement 1), 4542–4544. https://doi.org/10.1182/blood-2022-169416

EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC

Journal of Thoracic Oncology / Sep 01, 2022

Huang, Y., Zhao, J. J., Soon, Y. Y., Kee, A., Tay, S. H., Aminkeng, F., Ang, Y., Wong, A., Goh, B. C., & Soo, R. (2022). EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC. Journal of Thoracic Oncology, 17(9), S391. https://doi.org/10.1016/j.jtho.2022.07.673

Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patients.

Journal of Clinical Oncology / Jun 01, 2022

Huang, Y., Aminkeng, F., Wong, A. S. C., Tay, S. H., Zhao, J. J., Ang, Y., Soo, R. A., & Goh, B. C. (2022). Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patients. Journal of Clinical Oncology, 40(16_suppl), 2547–2547. https://doi.org/10.1200/jco.2022.40.16_suppl.2547

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

Journal of Thoracic Oncology / Mar 01, 2021

Huang, Y., Soon, Y. Y., Aminkeng, F., Tay, S. H., Ang, Y., Goh, B. C., Wong, A., & Soo, R. A. (2021). P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients. Journal of Thoracic Oncology, 16(3), S577. https://doi.org/10.1016/j.jtho.2021.01.1044

Pharmacogenomic Prediction of Bleomycin-Induced Pneumonitis in South East Asian Hodgkin Lymphoma Patients

Blood / Nov 29, 2018

Lee, J. S. X., Poon, L. M., Liu, X., Yuen, Y. C., Somasundaram, N., Chin, S. T., Teoh, C. M., Yan, B., Chan, H. L. E. H. L., Chee, Y.-L., Tang, T., Farzana, N., Aw, C. H. T., Khor, C. C., Ngeow, J. Y. Y., Ong, C. K., Tai, E. S., Chng, W. J., Goh, B. C., … Aminkeng, F. (2018). Pharmacogenomic Prediction of Bleomycin-Induced Pneumonitis in South East Asian Hodgkin Lymphoma Patients. Blood, 132(Supplement 1), 4111–4111. https://doi.org/10.1182/blood-2018-99-113952

Pharmacogenomic Prediction of Cisplatin-Induced Nephrotoxicity in Patients Treated for Childhood Cancer

Journal of Pharmacological and Toxicological Methods / Nov 01, 2017

Medeiros, M., Aminkeng, F., Jimenez-Triana, C., Rivas-Ruiz, R., Juarez, L., Palomo, M., Clark, P., Castañeda-Hernandez, G., Ross, C., & Carleton, B. (2017). Pharmacogenomic Prediction of Cisplatin-Induced Nephrotoxicity in Patients Treated for Childhood Cancer. Journal of Pharmacological and Toxicological Methods, 88, 173–174. https://doi.org/10.1016/j.vascn.2017.09.021

Pharmacogenomic Prediction of Ribavirin-Induced Hemolytic Anemia in Patients Treated for Hepatitis C Infection

Journal of Pharmacological and Toxicological Methods / Nov 01, 2017

Abel, S., Aminkeng, F., Kowalec, K., Drogemoller, B., Wright, G., Bader, R., Stortz, J., Yoshida, E., Lee, S., Al-Judaibi, B., Kim, R., Tam, E., Ramji, A., Ross, C., & Carleton, B. (2017). Pharmacogenomic Prediction of Ribavirin-Induced Hemolytic Anemia in Patients Treated for Hepatitis C Infection. Journal of Pharmacological and Toxicological Methods, 88, 167. https://doi.org/10.1016/j.vascn.2017.09.002

Genetic Variation in SLC16A5 Confers Protection from Cisplatin-Induced Ototoxicity in Adult Testicular Cancer Patients

Journal of Pharmacological and Toxicological Methods / Nov 01, 2017

Drogemoller, B., Monzon, J., Bhavsar, A., Borrie, A., Brooks, B., Wright, G., Liu, G., Fadhel, E., Renouf, D., Kollmannsberger, C., Bedard, P., Aminkeng, F., Hildebrand, C., Gunaretnam, E., Critchley, C., Chen, Z., Brunham, L., Hayden, M., Ross, C., … Carleton, B. (2017). Genetic Variation in SLC16A5 Confers Protection from Cisplatin-Induced Ototoxicity in Adult Testicular Cancer Patients. Journal of Pharmacological and Toxicological Methods, 88, 169–170. https://doi.org/10.1016/j.vascn.2017.09.010

Multifactorial Prediction of Anthracycline-Induced Cardiotoxicity in Childhood Cancer: 10 Years of Active Surveillance and Pharmacogenomics Studies at the Canadian Pharmacogenomics Network for Drug Safety

Journal of Pharmacological and Toxicological Methods / Nov 01, 2017

Aminkeng, F., Rassekh, S., Bhavsar, A., Luo, H., Wright, G., Drögemöller, B., Rieder, M., Hayden, M., Ross, C., & Carleton, B. (2017). Multifactorial Prediction of Anthracycline-Induced Cardiotoxicity in Childhood Cancer: 10 Years of Active Surveillance and Pharmacogenomics Studies at the Canadian Pharmacogenomics Network for Drug Safety. Journal of Pharmacological and Toxicological Methods, 88, 168. https://doi.org/10.1016/j.vascn.2017.09.005

OP13 Association entre le polymorphisme rs7903146(C/T) du gène TCF7L2 et l'obésité dans une population Camerounaise

Diabetes Research and Clinical Practice / Feb 01, 2014

Metsadjio, A. N., Sobngwi, E., Sontsa, O. D., Dongwi, E. N., Mato, E. P. M., Fokeng, M. G., Pokam, P. F., Djahmeni, E., Tiedeu, B. A., Evehe, M. S., Djokam-Dadjeu, R., Aminkeng, F., Mbacham, W. F., & Mbanya, J. C. (2014). OP13 Association entre le polymorphisme rs7903146(C/T) du gène TCF7L2 et l’obésité dans une population Camerounaise. Diabetes Research and Clinical Practice, 103, S12. https://doi.org/10.1016/s0168-8227(14)70040-3

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

Cancers / May 12, 2023

Huang, Y., Zhao, J. J., Soon, Y. Y., Kee, A., Tay, S. H., Aminkeng, F., Ang, Y., Wong, A. S. C., Bharwani, L. D., Goh, B. C., & Soo, R. A. (2023). Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Cancers, 15(10), 2733. https://doi.org/10.3390/cancers15102733

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines

Pediatric Blood & Cancer / Dec 22, 2017

Dionne, F., Aminkeng, F., Bhavsar, A. P., Groeneweg, G., Smith, A., Visscher, H., Rassekh, S. R., Ross, C., & Carleton, B. (2017). An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. Pediatric Blood & Cancer, 65(3). Portico. https://doi.org/10.1002/pbc.26887

DLL4 loss‐of‐function heterozygous mutations cause Adams–Oliver syndrome

Clinical Genetics / Oct 16, 2015

Aminkeng, F. (2015). DLL4 loss‐of‐function heterozygous mutations cause Adams–Oliver syndrome. Clinical Genetics, 88(6), 532–532. Portico. https://doi.org/10.1111/cge.12681

PDGFRB mutation causes autosomal‐dominant Penttinen syndrome

Clinical Genetics / Oct 27, 2015

Aminkeng, F. (2015). <scp>PDGFRB</scp> mutation causes autosomal‐dominant Penttinen syndrome. Clinical Genetics, 88(6), 531–531. Portico. https://doi.org/10.1111/cge.12680

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

Nature Genetics / Aug 03, 2015

Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Amstutz, U., Rieder, M. J., Bernstein, D., Carleton, B. C., Hayden, M. R., Ross, C. J. D., Hayden, M. R., … Carleton, B. C. (2015). A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics, 47(9), 1079–1084. https://doi.org/10.1038/ng.3374

Association between the rs12255372 variant of the TCF7L2 gene and obesity in a Cameroonian population

BMC Research Notes / Nov 25, 2015

Ngwa, E. N., Sobngwi, E., Atogho-Tiedeu, B., Noubiap, J. J. N., Donfack, O. S., Guewo-Fokeng, M., Mofo, E. P. M., Fosso, P. P., Djahmeni, E., Djokam-Dadjeu, R., Evehe, M.-S., Aminkeng, F., Mbacham, W. F., & Mbanya, J. C. (2015). Association between the rs12255372 variant of the TCF7L2 gene and obesity in a Cameroonian population. BMC Research Notes, 8(1). https://doi.org/10.1186/s13104-015-1661-3

EIF2AK4 genetic mutations cause a recessive form of rare and deadly lung disease, pulmonary veno‐occlusive disease

Clinical Genetics / Jul 21, 2014

Aminkeng, F. (2014). <scp>EIF2AK4</scp> genetic mutations cause a recessive form of rare and deadly lung disease, pulmonary veno‐occlusive disease. Clinical Genetics, 86(3), 218–219. Portico. https://doi.org/10.1111/cge.12446

GFI1B mutation causes autosomal dominant gray platelet syndrome

Clinical Genetics / Apr 09, 2014

Aminkeng, F. (2014). <scp>GFI1B</scp> mutation causes autosomal dominant gray platelet syndrome. Clinical Genetics, 85(6), 534–535. Portico. https://doi.org/10.1111/cge.12380

Using pharmacogenetics in real time to guide therapy: the warfarin example

Clinical Genetics / Apr 09, 2014

Aminkeng, F. (2014). Using pharmacogenetics in real time to guide therapy: the warfarin example. Clinical Genetics, 85(6), 533–534. Portico. https://doi.org/10.1111/cge.12378

WDR45 mutations define a novel disease entity—Static Encephalopathy of Childhood with Neurodegeneration in Adulthood

Clinical Genetics / May 29, 2013

Aminkeng, F. (2013). <scp>WDR45</scp> mutations define a novel disease entity—Static Encephalopathy of Childhood with Neurodegeneration in Adulthood. Clinical Genetics, 84(3), 209–209. Portico. https://doi.org/10.1111/cge.12183

KCNT1 mutations in ADNFLE and MMPSI: a new driver in the etiology and pathophysiology of early‐onset epileptic syndromes

Clinical Genetics / Apr 01, 2013

Aminkeng, F. (2013). <scp>KCNT1</scp> mutations in <scp>ADNFLE</scp> and <scp>MMPSI</scp>: a new driver in the etiology and pathophysiology of early‐onset epileptic syndromes. Clinical Genetics, 83(4), 319–320. Portico. https://doi.org/10.1111/cge.12082

Mutations in ATP1A3 cause alternating hemiplegia of childhood

Clinical Genetics / Jan 01, 2013

Aminkeng, F. (2013). Mutations in <scp>ATP1A3</scp> cause alternating hemiplegia of childhood. Clinical Genetics, 83(1), 32–33. Portico. https://doi.org/10.1111/cge.12031

TNFa microsatellite polymorphism modulates the risk of type 1 diabetes in the Belgian population, independent of HLA-DQ

Human Immunology / Aug 01, 2007

Aminkeng, F., Van Autreve, J. E., Koeleman, B. P. C., Quartier, E., Van Schravendijk, C., Gorus, F. K., & Van der Auwera, B. J. R. (2007). TNFa microsatellite polymorphism modulates the risk of type 1 diabetes in the Belgian population, independent of HLA-DQ. Human Immunology, 68(8), 690–697. https://doi.org/10.1016/j.humimm.2007.05.001

Education

Vrije Universiteit Brussel

Doctor in Medical Sciences, Medical Biochemistry and Diabetes Research Centre / September, 2010

Brussel

Vrije Universiteit Brussel

Master Degree in Medical and Pharmaceutical Research, Medical Biochemsitry and Diabetes Research Centre / June, 2005

Brussel

University of Buea

Bachelor of Medical Laboratory Science, Medical Laboratory Science / August, 2001

Buea

Experience

Medical College of Wisconsin

Associate Professor / March, 2024 — Present

Principal Investigator / March, 2024 — Present

National University of Singapore

Faculty / August, 2021 — February, 2024

Assistant Professor / April, 2020 — February, 2024

Adjunct Assistant Professor / July, 2018 — December, 2019

Adjunct Assistant Professor / January, 2018 — December, 2019

National University Health System

Faculty / April, 2020 — February, 2024

Agency for Science, Technology and Research

Head - Pharmacogenomics and Personalized Medicine Program / February, 2017 — December, 2019

Assistant Principal Investigator / February, 2017 — December, 2019

University of British Columbia

Research Associate / April, 2016 — January, 2017

Postdoctoral Fellow / February, 2011 — March, 2016

University of Ottawa

Postdoctoral Fellow / December, 2010 — February, 2011

Links & Social Media

Research Web Site

Yong Loo Lin School of Medicine, National University of Singapore

Centre for Personalized and Precision Health, National University Health System

ORCID

Join FOLEFAC AMINKENG on NotedSource!

Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.

Expert Institutions

Proudly trusted by

Connect with researchers and scientists like A/Prof FOLEFAC AMINKENG on NotedSource to help your company with innovation, research, R&D, L&D, and more.